ALLMedicine™ Glioblastoma Multiforme Center
Research & Reviews 2,346 results
https://doi.org/10.1158/1535-7163.MCT-22-0066
Molecular Cancer Therapeutics; Kannappan V, Liu Y et. al.
May 18th, 2022 - Glioblastoma stem cell (GSC) is the major cause of glioblastoma multiforme (GBM) chemotherapy failure. Hypoxia is one of the determinants of GSC. NFκB plays a pivotal link between hypoxia and cancer stem cells (CSCs). Disulfiram (DS), an antialcoh...
https://doi.org/10.1007/s12032-022-01693-0
Medical Oncology (Northwood, London, England); Shahcheraghi SH, Salemi F et. al.
May 15th, 2022 - Glioblastoma multiforme (GBM) grade IV glioma is the most frequent and deadly intracranial cancer. This tumor is determined by unrestrained progression, uncontroled angiogenesis, high infiltration and weak response to treatment, which is chiefly b...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102128
Technology in Cancer Research & Treatment; Wang J, Yan S et. al.
May 12th, 2022 - Glioblastoma multiforme (GBM) is the most malignant primary brain tumor in adults. This study aimed to identify significant prognostic biomarkers related to GBM. We collected 3 GBM and 3 healthy human brain samples for transcriptome and proteomic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086421
Journal of Experimental & Clinical Cancer Research : CR; Song J, Zheng J et. al.
May 11th, 2022 - RNA-binding proteins (RBPs) and circular RNAs (circRNAs) play important roles in glioblastoma multiforme (GBM). Aerobic glycolysis is a metabolic characteristic of GBM. However, the roles of RBPs and circRNAs in aerobic glycolysis in GBM remain un...
https://clinicaltrials.gov/ct2/show/NCT01269424
May 10th, 2022 - OBJECTIVES: Primary To evaluate the feasibility of introducing and expressing P140K MGMT cDNA from a lentiviral-based provirus in autologous hematopoietic stem cells harvested from Glioblastoma multiforme (GBM) patients. To assess the safety assoc...
Guidelines 1 results
https://doi.org/10.1007/s11060-013-1337-6
Journal of Neuro-oncology; Ryu S, Buatti JM et. al.
Apr 15th, 2014 - Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiati...
Drugs 5 results see all →
Clinicaltrials.gov 155 results
https://clinicaltrials.gov/ct2/show/NCT01269424
May 10th, 2022 - OBJECTIVES: Primary To evaluate the feasibility of introducing and expressing P140K MGMT cDNA from a lentiviral-based provirus in autologous hematopoietic stem cells harvested from Glioblastoma multiforme (GBM) patients. To assess the safety assoc...
https://clinicaltrials.gov/ct2/show/NCT04782609
May 9th, 2022 - This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation des...
https://clinicaltrials.gov/ct2/show/NCT04926168
May 6th, 2022 - Recent phase III trials in patients with newly diagnosed patients with glioblastoma have demonstrated that adding new agents (such as cilengitide, bevacizumab, or nivolumab) to standard radiation and TMZ do not improve survival in this disease. Th...
https://clinicaltrials.gov/ct2/show/NCT01535911
May 2nd, 2022 - Summary: The current standard of care for glioblastoma multiforme (GBM), the most common primary brain tumor in adults, includes surgical resection, radiation and chemotherapy. Survival rarely exceeds 18 months. The investigators propose to test t...
https://clinicaltrials.gov/ct2/show/NCT02152982
Apr 29th, 2022 - PRIMARY OBJECTIVE: I. Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ (temozolomide), compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed glioblastoma m...
News 118 results
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma
Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...
https://www.onclive.com/view/fda-grants-fast-track-designation-to-cynk-101-for-her2-gastric-gej-cancers
Jan 19th, 2022 - The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab (Herceptin), and pembrolizumab (Keytruda) for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ)...
https://www.onclive.com/view/fda-grants-fast-track-designation-to-st101-for-recurrent-glioblastoma
Dec 6th, 2021 - The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma, according to an announcement from Sapience Therapeutics, Inc., the drug developer.1 The decision is ...
https://www.onclive.com/view/advanced-3d-mri-technology-marks-a-leap-forward-in-glioblastoma-imaging
Oct 6th, 2021 - Hui-Kuo Shu, MD, PhD Associate Professor Although advances have been made in imaging techniques for patients with glioblastoma multiforme (GBM), new tools are needed to supplement standard imaging sequences. Researchers at the Winship Cancer...
https://www.onclive.com/view/dendritic-cell-vaccines-offer-promising-signals-as-glioblastoma-therapy
Oct 6th, 2021 - Arnold Etame, MD, PhD Moffitt Cancer Center Neuro- Oncology Program Tampa, FL Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common...
